Flunoxaprofen isocyanate | CAS# 125836-69-3 | Biochemical

MedKoo Cat#: 575546 | Name: Flunoxaprofen isocyanate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Flunoxaprofen isocyanate is a chiral nonsteroidal anti-inflammatory drug (NSAID) that is closely related to naproxen. Flunoxaprofen has been shown to significantly improve the symptoms of osteoarthritis and rheumatoid arthritis.

Chemical Structure

Flunoxaprofen isocyanate

CAS#125836-69-3

Theoretical Analysis

MedKoo Cat#: 575546

Name: Flunoxaprofen isocyanate

CAS#: 125836-69-3

Chemical Formula: C16H11FN2O2

Exact Mass: 282.0805

Molecular Weight: 282.27

Elemental Analysis: C, 68.08; H, 3.93; F, 6.73; N, 9.92; O, 11.34

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Flunoxaprofen isocyanate

IUPAC/Chemical Name

Benzoxazole, 2-(4-fluorophenyl)-5-(1-isocyanatoethyl)-, (S)-

InChi Key

UFVXLFRBVOVOFV-JTQLQIEISA-N

InChi Code

InChI=1S/C16H11FN2O2/c1-10(18-9-20)12-4-7-15-14(8-12)19-16(21-15)11-2-5-13(17)6-3-11/h2-8,10H,1H3/t10-/m0/s1

SMILES Code

C[C@H](N=C=O)c1ccc2oc(nc2c1)c3ccc(F)cc3

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 282.27 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Furlanut M, Montanari G, Perosa A, Velussi C, Forgione A, Palatini P. Absorption and disposition kinetics of flunoxaprofen and benoxaprofen in healthy volunteers. Int J Clin Pharmacol Res. 1985;5(3):165-70. PubMed PMID: 4018949. 2: Grillo MP, Wait JC, Tadano Lohr M, Khera S, Benet LZ. Stereoselective flunoxaprofen-S-acyl-glutathione thioester formation mediated by acyl-CoA formation in rat hepatocytes. Drug Metab Dispos. 2010 Jan;38(1):133-42. doi: 10.1124/dmd.109.029371. PubMed PMID: 19786506; PubMed Central PMCID: PMC2802421. 3: Cecchini G, Ferutta P, Soldà A, Ragazzi G. [Non-specific vaginitis and topical treatment. Comparison of flunoxaprofen and benzydamine]. Minerva Ginecol. 1989 Jun;41(6):287-90. Italian. PubMed PMID: 2671808. 4: Iwakawa S, Spahn H, Benet LZ, Lin ET. Stereoselective disposition of carprofen, flunoxaprofen, and naproxen in rats. Drug Metab Dispos. 1991 Sep-Oct;19(5):853-7. PubMed PMID: 1686227. 5: Fioravanti A, Giordano N, Megale F, Jovane D, Franci A, Marcolongo R. [Efficacy and tolerability of flunoxaprofen in the treatment of rheumatoid arthritis. A cross-over clinical study using naproxen]. Clin Ter. 1989 Oct 31;131(2):83-91. Italian. PubMed PMID: 2533024. 6: Dahms M, Spahn-Langguth H. Covalent binding of acidic drugs via reactive intermediates: detection of benoxaprofen and flunoxaprofen protein adducts in biological material. Pharmazie. 1996 Nov;51(11):874-81. PubMed PMID: 8985978. 7: Facchini V, Rispoli G, Dubini F, Bignami P, Sacchi C. [Activity of topical flunoxaprofen in nonspecific vaginitis. Comparison with meclocycline sulfosalicylate]. Minerva Ginecol. 1989 Dec;41(12):609-14. Italian. PubMed PMID: 2626206. 8: Dong JQ, Smith PC. Glucuronidation and covalent protein binding of benoxaprofen and flunoxaprofen in sandwich-cultured rat and human hepatocytes. Drug Metab Dispos. 2009 Dec;37(12):2314-22. doi: 10.1124/dmd.109.028944. Epub 2009 Sep 22. PubMed PMID: 19773537; PubMed Central PMCID: PMC2784705. 9: Pedrazzini S, De Angelis M, Muciaccia WZ, Sacchi C, Forgione A. Stereochemical pharmacokinetics of the 2-arylpropionic acid non-steroidal antiinflammatory drug flunoxaprofen in rats and in man. Arzneimittelforschung. 1988 Aug;38(8):1170-5. PubMed PMID: 3196413. 10: Dong JQ, Liu J, Smith PC. Role of benoxaprofen and flunoxaprofen acyl glucuronides in covalent binding to rat plasma and liver proteins in vivo. Biochem Pharmacol. 2005 Sep 15;70(6):937-48. PubMed PMID: 16046212. 11: Palatini P, Montanari G, Perosa A, Forgione A, Pedrazzini S, Furlanut M. Stereospecific disposition of flunoxaprofen enantiomers in human beings. Int J Clin Pharmacol Res. 1988;8(3):161-7. PubMed PMID: 3403103. 12: Filippelli A, Marrazzo R, Susanna V, Cenicola ML, Servodio R, Romano AR, Molinario L, Russo S, Marmo E. Influence of rat prenatal and postnatal exposure to a non-steroidal anti-inflammatory agent (flunoxaprofen) on cardiovascular function in the progeny. Prostaglandins Leukot Essent Fatty Acids. 1989 Jul;37(1):15-22. PubMed PMID: 2762365. 13: Berti F, Galli G, Omini C, Rossoni G, Brunelli G, Daffonchio L, Viganò T, Magni F, Crivellari MT, Forgione A, et al. Interference of the new antiinflammatory compound flunoxaprofen with eicosanoid formation in various biological systems. Arzneimittelforschung. 1987 Jan;37(1):27-32. PubMed PMID: 3566853. 14: Van Rensburg AJ, Theron AJ, Anderson R. Comparison of the pro-oxidative interactions of flunoxaprofen and benoxaprofen with human polymorphonuclear leucocytes in vitro. Agents Actions. 1991 Jul;33(3-4):292-9. PubMed PMID: 1950816. 15: Lisa M, Losasso C, Conte GF, Loffreda A, de Novellis V, Carapella N. Interference of flunoxaprofen, a non-steroidal anti-inflammatory agent, on the antihypertensive activity of etozoline. Pharmacol Res Commun. 1988 Dec;20(12):1125-6. PubMed PMID: 3212004. 16: Rossi F, Filippelli A, Stella L, Vacca C, Lampa E. Effects of flunoxaprofen, a non-steroidal anti-inflammatory agent, on the cardiovascular system. J Med. 1992;23(5):315-26. PubMed PMID: 1469334. 17: Pedrazzini S, Zanoboni-Muciaccia W, Sacchi C, Forgione A. Determination of flunoxaprofen enantiomers in biological fluids by high-performance liquid chromatography. J Chromatogr. 1987 Mar 20;415(1):214-20. PubMed PMID: 3584360. 18: Capone M, Martinelli F. [Medium- and long-term clinical study on the use of the new non-steroidal anti-inflammatory drug flunoxaprofen in osteoarthrosis]. Minerva Med. 1987 Aug 31;78(16):1219-25. Italian. PubMed PMID: 3627532. 19: Spahn H. S-(+)-flunoxaprofen chloride as chiral fluorescent reagent. J Chromatogr. 1988 May 13;427(1):131-7. PubMed PMID: 3410893. 20: Forgione A, Zanoboni A, Zanoboni-Muciaccia W, Sacchi C, Pupita F. Multicentre clinical study with flunoxaprofen in osteoarthritis: preliminary data on 154 patients. Int J Clin Pharmacol Res. 1985;5(1):51-8. PubMed PMID: 3888865.